Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CetuGEX plus platinum-based chemotherapy versus cetuximab plus platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma
2013-003695-13Phase 2Terminated
- Sponsor
- Glycotope
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tomuzotuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Glycotope. Primary endpoint: progression-free survival. Started Oct 2013; status: terminated.
02
Drugs
tomuzotuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2013-003695-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003695-13.